Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt’s lymphoma cells

被引:0
|
作者
Mei Hong
Yoshihiro Murai
Tomohiko Kutsuna
Hiroyuki Takahashi
Kazuhiro Nomoto
Chun-Mei Cheng
Shin Ishizawa
Qing-Li Zhao
Ryohei Ogawa
Brian V. Harmon
Koichi Tsuneyama
Yasuo Takano
机构
[1] Toyama Medical and Pharmaceutical University,Department of Pathology, School of Medicine
[2] Toyama Medical and Pharmaceutical University,Department of Radiological Sciences, School of Medicine
[3] Queensland University of Technology,School of Life Sciences
来源
Journal of Cancer Research and Clinical Oncology | 2006年 / 132卷
关键词
EBV; EBNA1; RNA interference; Burkitt’s lymphoma; Cell growth;
D O I
暂无
中图分类号
学科分类号
摘要
Purpose: Epstein-Barr virus (EBV) is associated with the development of several lymphoid and epithelial malignancies, including Burkitt’s lymphoma. The EBV latent protein, EBV Nuclear Antigen 1 (EBNA1), is detectable in almost all types of EBV-associated tumors and is essential for replication and maintenance of the latent episome of EBV. We here examined whether the RNA interference (RNAi) technique could be employed to suppress expression of EBNA1 in EBV-positive Burkitt’s lymphoma cells. Methods: A Raji cell line expressing small hairpin RNAs (shRNAs) against EBNA1 was established and EBNA1 mRNA level was determined by real-time RT-PCR analysis. We investigated the effects of EBNA1 silence on lymphoma cell growth and cell cycle progression. Results: Transfection of an EBNA1 RNAi plasmid resulted in substantial loss of EBNA1 mRNA and significantly inhibited proliferation of Raji cells relative to the control plasmid case. Suppression of EBNA1 was also associated with downregulation of EBV oncogene EBNA2, a decreased PCNA labeling index and increased G0/G1 fraction in cell cycle analysis. Conclusions: These findings point to potential therapeutic applications for vector-mediated siRNA delivery to control EBV-associated malignant disorders.
引用
收藏
页码:1 / 8
页数:7
相关论文
共 48 条
  • [21] IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus BZLF1 transcription in Akata Burkitt's lymphoma cells
    Jordi, Marc
    Marty, Jeannine
    Mordasini, Vanessa
    Lunemann, Anna
    McComb, Scott
    Bernasconi, Michele
    Nadal, David
    PLOS ONE, 2017, 12 (10):
  • [22] Downregulation of the polyamine regulator spermidine/spermine N1-acetyltransferase by Epstein-Barr virus in a Burkitt's lymphoma cell line
    Shi, Mingxia
    Gan, Yan-jun
    Davis, Timothy O.
    Scott, Rona S.
    VIRUS RESEARCH, 2013, 177 (01) : 11 - 21
  • [23] Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein–Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells
    B Renouf
    É Hollville
    A Pujals
    C Tétaud
    J Garibal
    J Wiels
    Leukemia, 2009, 23 : 1557 - 1563
  • [24] Lentivirus-mediated RNA interference targeting EBNA1 gene inhibits the growth of GT-38 cells in vitro and in vivo
    Wang, Jian
    Liang, Cunfu
    Meng, Fansheng
    Xu, Xiangwen
    Wu, Yan
    Lu, Lin
    ONCOLOGY LETTERS, 2019, 18 (03) : 2286 - 2291
  • [25] Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma
    Parolini, O
    Kagerbauer, B
    Simonitsch-Klupp, I
    Ambros, P
    Jaeger, U
    Mann, G
    Haas, OA
    Morra, M
    Gadner, H
    Terhorst, C
    Knapp, W
    Holter, W
    ANNALS OF HEMATOLOGY, 2002, 81 (08) : 441 - 447
  • [26] Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: Implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells
    Jochner, N
    Eick, D
    ZimberStrobl, U
    Pawlita, M
    Bornkamm, GW
    Kempkes, B
    EMBO JOURNAL, 1996, 15 (02): : 375 - 382
  • [27] A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1)
    Rubicz, Rohina
    Yolken, Robert
    Drigalenko, Eugene
    Carless, Melanie A.
    Dyer, Thomas D.
    Bauman, Lara
    Melton, Phillip E.
    Kent, Jack W., Jr.
    Harley, John B.
    Curran, Joanne E.
    Johnson, Matthew P.
    Cole, Shelley A.
    Almasy, Laura
    Moses, Eric K.
    Dhurandhar, Nikhil V.
    Kraig, Ellen
    Blangero, John
    Leach, Charles T.
    Goering, Harald H. H.
    PLOS GENETICS, 2013, 9 (01):
  • [28] Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines
    Perez-Chacon, Gema
    de los Rios, Cristobal
    Zapata, Juan M.
    PHARMACOLOGICAL RESEARCH, 2014, 89 : 46 - 56
  • [29] Development of a monoclonal antibody against Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) that can detect EBNA-LP expressed in P3HR1 cells
    Shaku, F
    Matsuda, G
    Furuya, R
    Kamagata, C
    Igarashi, M
    Tanaka, M
    Kanamori, M
    Nishiyama, Y
    Yamamoto, N
    Kawaguchi, Y
    MICROBIOLOGY AND IMMUNOLOGY, 2005, 49 (05) : 477 - 483
  • [30] The AT-rich region between-54 to-66 is important for the promoter activity of interleukin-10 in Epstein-Barr virus positive Burkitt's lymphoma cells
    Kube, D
    Laser, H
    von Knethen, A
    Tesch, H
    GENES AND IMMUNITY, 1999, 1 (02) : 105 - 114